(19)
(11) EP 2 844 642 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.12.2019 Bulletin 2019/52

(45) Mention of the grant of the patent:
13.11.2019 Bulletin 2019/46

(21) Application number: 13788352.6

(22) Date of filing: 15.03.2013
(51) International Patent Classification (IPC): 
C07D 239/48(2006.01)
C07F 9/6561(2006.01)
C07F 9/6512(2006.01)
A61K 31/505(2006.01)
A61P 35/00(2006.01)
 C07D 403/12(2006.01)
C07F 9/6584(2006.01)
C07F 9/6521(2006.01)
A61K 31/506(2006.01)
(86) International application number:
PCT/US2013/032713
(87) International publication number:
WO 2013/169401 (14.11.2013 Gazette 2013/46)

(54)

COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS

VERFAHREN ZUR HEMMUNG DER ZELLPROLIFERATION BEI EFGR-VERMITTELTEM KREBS

COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 05.05.2012 US 201261643228 P
07.11.2012 US 201261723779 P
08.11.2012 US 201261724283 P

(43) Date of publication of application:
11.03.2015 Bulletin 2015/11

(73) Proprietor: ARIAD PHARMACEUTICALS, INC.
Cambridge, MA 02139-4234 (US)

(72) Inventors:
  • ZHU, Xiaotian
    Newton, MA 02465 (US)
  • WANG, Yihan
    Newton, MA 02460 (US)
  • SHAKESPEARE, William, C.
    Southborough, MA 01772 (US)
  • HUANG, Wei-Sheng
    Acton, MA 01720 (US)
  • DALGARNO, David, C.
    Brookline, MA 02446 (US)

(74) Representative: D Young & Co LLP 
120 Holborn
London EC1N 2DY
London EC1N 2DY (GB)


(56) References cited: : 
WO-A1-2009/143389
WO-A1-2012/051587
US-A1- 2012 094 999
 WO-A1-2011/090760
US-A1- 2011 230 494
US-A1- 2012 316 135
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).